NCT01508923View on ClinicalTrials.gov

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

February 28, 2002

Study Completion Date

February 28, 2002

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

DRUG

placebo

6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Trial Locations (1)

8000

Novo Nordisk Investigational Site, Århus C

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY